Bronchobos syrup

Land: Armenía

Tungumál: enska

Heimild: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Virkt innihaldsefni:

carbocisteine

Fáanlegur frá:

Bosnalijek d.d.

ATC númer:

R05CB03

INN (Alþjóðlegt nafn):

carbocisteine

Skammtar:

250mg/5ml

Lyfjaform:

syrup

Einingar í pakka:

250ml glass bottle (200ml syrup) and measuring spoon

Gerð lyfseðils:

OTC

Leyfisstaða:

Registered

Leyfisdagur:

2016-08-30

Vara einkenni

1.
NAME OF THE MEDICINAL PRODUCT
BRONCHOBOS
®
250 mg/5 ml syrup
carbocisteine
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5 ml of syrup contains: Carbocisteine 250 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Syrup (clear, slightly viscous solution with raspberry color and
odor).
4.
CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS
Carbocisteine is a mucolytic agent for the adjunctive therapy of
respiratory tract disorders
characterised by excessive, viscous mucus, including chronic
obstructive airways disease.
4.2. POSOLOGY AND METHOD OF ADMINISTRATION
_ADULTS INCLUDING THE ELDERLY:_
Dosage is based upon an initial daily dosage of 2250 mg carbocisteine
in divided doses, reducing
to 1500 mg daily in divided doses when a satisfactory response is
obtained e.g. 15 ml tds reducing
to 10 ml tds.
_CHILDREN:_
BRONCHOBOS 250 mg/5 ml syrup is intended for
children over 12 years of age, in doses
recommended for adults.
BRONCHOBOS 125 mg/5 ml syrup is intended for children under 12 years
of age.
METHOD OF ADMINISTRATION
BRONCHOBOS 250 mg/5 ml syrup is for oral use.
1.3.1 Summary of Product Characteristics
SmPCD004207/1
BRONCHOBOS 250 mg/5 ml syrup
Page: 1 / 6
1.3.1 Summary of Product Characteristics
SmPCD004207/1
BRONCHOBOS 250 mg/5 ml syrup
Page: 1 / 6
_NOTE: _

For dosage of BRONCHOBOS 250 mg/5 ml syrup a 5 ml dosing spoon
graduated at 2.5 ml
and supplied in the box is used. Each dosing spoon of BRONCHOBOS 250
mg/5 ml syrup
contains 250 mg carbocisteine.
4.3.
CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients.

Use in patients with active peptic ulceration.
4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Caution is recommended in the elderly, in those with a history of
gastroduodenal ulcers, or
those
taking
concomitant
medications
known
to
cause
gastrointestinal
bleeding.
If
gastrointestinal bleeding occurs, patients should discontinue
medication.

BRONCHOBOS 250 mg/5 ml syrup contains ethanol 96% (alcohol). In
keeping with the
dosage in